At TAAV we produce enzymatic DNA as an alternative to plasmids DNA for the manufacture of adeno-associated virus (AAV). This disruptive technology is creating a new industry standard for transfection-based rAAV production.
The synthetic process we use leads to high yields shortening manufacturing timelines, facilitating quicker production of rAAV and potentially increasing safety by virtually eliminating bacterial sequences that are present when using plasmid DNA.
neDNA™ is designed to transform and accelerate the traditional gene therapy development timelines
Gene therapies are expected to experiment significant advances in the upcoming years.
These breakthrough innovations are reshaping how we address previously untreatable diseases transforming people’s lives.
After many decades of work, the future of gene therapy is incredibly promising.
Let’s work together to make it real.
Our team of experts has breadth and depth of experience providing AAV therapeutic developers with our innovative enzymatic DNA to support their manufacturing of AAV based therapies.
We provide neDNA™ at three quality grades to support various phases from R&D to clinical development.
The starting point in our neDNA™ manufacturing process is a precursor plasmid produce in our facility.
That contains the unique neDNA™ elements for production and processing.
The initial step is the denaturation of the neDNA™ precursor plasmid to obtain two single DNA strands.
Next, we add the polymerase that copies the template incorporating nucleotides
Once long DNA concatemers have been generated, we add restriction enzymes to process backbone sequences.
Telomerase (TelN) covalently close both ends of the gene of interest producing the neDNA™ molecules.
Finally, we add exonucleases to digest all open-ended DNA, leaving the neDNA™ intact.
The purification process removes all impurities, leaving the final neDNA™ product.
We believe neDNA™ is a likely safer, more scalable, robust and faster way to manufacture AAV, and produces higher yield.
Plasmids have several major bottlenecks in gene therapy manufacturing, and one specifically that we solve with neDNA™: Production of plasmids may result in their genetic instability, which makes them susceptible to changes in sequence, particularly when encoding complex viral vectors.
Our neDNA™ approach intends to be safer producing higher and faster yields at lower costs than plasmid.
neDNA™ is produced enzymatically and eliminates bacterial sequences, thus preventing aberrant packaging of bacterial origins of replication and antibiotic resistance genes.
neDNA™ production obtains more copies per gram of your sequence of interest, enabling you to transfect what you need.
Also, the total amount of DNA needed for transfection is reduced.
Producing comparable rAAV yields.
neDNA™ is manufactured from milligram to multi-gram scale with an identical process, in the same facility – Production increases to match need.
neDNA™ is manufactured in days, rather than months, and PO to delivery will be less than 3 months in most cases.
Enables batch-to-batch consistency.
Enzymatic DNA Manufacturing.
Send us a message: email@example.com
Parque Científico y Tecnológico de Gipuzkoa Paseo Mikeletegi, 73 B 20009 San Sebastián, Spain